MyVisionTest

IOP spikes after Avastin injection attributed to compounding pharmacy

Mon, 26 Oct 2009 00:00:00 CST

How different compounding pharmacies prepare doses of Avastin may lead to differences in high molecular weight adducts that may plug outflow pathways or cause an immunologic response that leads to IOP spikes, a speaker said at American Academy of Ophthalmology. "By no means am I saying that...

Wet and dry AMD have similar impact on quality of life

Mon, 26 Oct 2009 00:00:00 CST

Although patients with dry age-related macular degeneration may have clinically superior vision than patients with wet AMD, the nonexudative form can nonetheless negatively affect the patient's functional vision, according to a speaker at the American Academy of Ophthalmology meeting. In a...

Noninfectious endophthalmitis is more common, less harmful than infectious endophthalmitis

Mon, 26 Oct 2009 00:00:00 CST

Noninfectious endophthalmitis after anti-VEGF therapy may represent a maturing immune response to repeated doses, according to a speaker at the American Academy of Ophthalmology meeting. While infectious endophthalmitis remains a pressing concern after anti-VEGF therapy because of its...

VEGF-Trap has longer duration of effect

Mon, 26 Oct 2009 00:00:00 CST

Data from the extension study of VEGF-Trap suggest clinically significant improvements in vision with low dosing burden and a favorable safety profile, according to a speaker at the American Academy of Ophthalmology meeting. In the CLEAR-IT 2 extension study, 117 patients were followed with...

Update on Lucentis clinical trials for retinal vein occlusion

Mon, 26 Oct 2009 00:00:00 CST

Genentech, Inc. announced results from two Phase III studies of Lucentis (ranibizumab) in macular edema due to retinal vein occlusion (RVO), which showed patients given Lucentis had significant improvement in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham...

Positive phase-1 clinical trial results for ISONEP in AMD

Mon, 26 Oct 2009 00:00:00 CST

Lpath, Inc. reported positive results of its single-dose Phase 1 clinical trial of iSONEP, an anti-sphingosine-1-phosphate monoclonal antibody, in neovascular age-related macular degeneration (AMD) patients. iSONEP met its primary endpoint of being well tolerated in all 15 patients at...